Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Novel Diagnostics for Ocular Structure

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2011 by University of Pittsburgh.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00286637
First received: February 2, 2006
Last updated: July 25, 2011
Last verified: July 2011
  Purpose

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases


Condition
Glaucoma
Macular Disease

Study Type: Observational
Official Title: Optical Coherence Tomography Domain Reflectometry & Optical Coherence Tomography Measurements of Intraocular Structure

Resource links provided by NLM:


Further study details as provided by University of Pittsburgh:

Estimated Enrollment: 500
Study Start Date: January 1995
Estimated Study Completion Date: May 2012
Estimated Primary Completion Date: May 2012 (Final data collection date for primary outcome measure)
Detailed Description:

The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Recruiting subjects male or female, ages beginning at 18 with Macular dgegeneration, diabetic retinopathy, and/or glaucoma. Can also be a normal/healthy subject.

Criteria

Inclusion Criteria:

  1. Age older than or equal to 18 years old
  2. Macular Degeneration, Diabetic Retinopathy, and/or glaucoma patients.
  3. Normal control subjects

Exclusion Criteria:

  1. Media opacity (lens, vitreous, cornea)
  2. Strabismus, nystagmus, or a condition that would prevent fixation.
  3. Inability to understand informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00286637

Contacts
Contact: Kristy A Truman 412-383-8778 trumank@upmc.edu
Contact: Melessa Salay 412-383-9884 salaymd@upmc.edu

Locations
United States, Pennsylvania
University of Pittsburgh UPMC Eye Center Recruiting
Pittsburgh, Pennsylvania, United States, 15213
Contact: Kristy A Truman    412-383-8778    trumank@upmc.edu   
Contact: Rose Clare Aubourg    412-383-3853      
Sub-Investigator: Joel S Schuman, MD         
Principal Investigator: Gadi Wollstein, MD         
Sub-Investigator: Hiroshi Ishikawa, MD         
Sponsors and Collaborators
University of Pittsburgh
Investigators
Study Chair: Joel S Schuman, MD University of Pittsburgh
  More Information

No publications provided by University of Pittsburgh

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Joel Schuman M.D. / Melessa Salay, UPMC Eye Center
ClinicalTrials.gov Identifier: NCT00286637     History of Changes
Other Study ID Numbers: RO1-EY013178-06, RO1-EY011289-21, P30-EY008098
Study First Received: February 2, 2006
Last Updated: July 25, 2011
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by University of Pittsburgh:
OCT
CSLO
SLP
Perimetry
electrophysiology
glaucoma
macular degeneration
retinopathy
diabetes
macular hole

Additional relevant MeSH terms:
Glaucoma
Eye Diseases
Ocular Hypertension

ClinicalTrials.gov processed this record on November 25, 2014